Bacteroides fragilis for relieving endotoxin infection and application thereof
US11628192B2 · kind B2 · utility
Assignee
Inventors
Key dates
| Filing date | Oct 28, 2020 |
| Grant date | Apr 18, 2023 |
| Priority date | — |
| Expiry date | Apr 29, 2041 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12R2001/01
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The disclosure discloses Bacteroides fragilis for relieving endotoxin infection and application thereof, and belongs to the technical field of microorganisms. The Bacteroides fragilis CCFM1020 of the disclosure has low immunogenicity, and can reduce the content of pro-inflammatory factors and increase the concentration of anti-inflammatory factors in the blood of hosts infected with endotoxin, up-regulate the number of Foxp3+ regulatory T cells and stabilize the composition of the intestinal microbiota. A pharmaceutical composition of the Bacteroides fragilis CCFM1020 for relieving endotoxin infection has broad application prospects.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.